NovaBay(R) Pharmaceuticals Appoints Professor John A. Soderquist, Ph.D. to its Scientific...

NovaBay(R) Pharmaceuticals Appoints Professor John A. Soderquist, Ph.D. to its
Scientific Advisory Board

EMERYVILLE, Calif., April 7 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals,
Inc. (NYSE-Amex: NBY) today announced the appointment of Professor John A.
Soderquist to the Company's Scientific Advisory Board. Dr. Soderquist, who is
currently Professor of Organic Chemistry in the Department of Chemistry at
University of Puerto Rico, is recognized worldwide as a thought leader and
pioneer in Synthetic Organic Chemistry.

"Dr. Soderquist brings extensive experience in modern synthetic methodologies
utilizing boron, silicon reagents to NovaBay," said Dr. Ron Najafi, NovaBay's
chairman and chief executive officer. "We are extremely honored to have a
scientist of the caliber of Professor Soderquist joining our Scientific
Advisory Board. His knowledge and advice will greatly assist NovaBay as we
continue to advance the development of our novel Aganocide(R) compounds to
treat and prevent a wide range of infections in multiple large markets, with
low potential for causing resistance."

Dr. Soderquist has been providing critical input to NovaBay on the development
of the Aganocide class of antimicrobial molecules specifically designed by
NovaBay to mimic the body's natural defense against infection. These
differentiated, stable, first-in-class compounds may deliver the same or
better level of antimicrobial activity than is currently reached by common
antibiotics, but without contributing to the growing rise in bacterial
resistance. The Aganocide compounds have shown in preclinical trials to be
highly effective against bacteria, viruses and fungi. They have also been
demonstrated to be effective against bacteria in biofilm, for which most
antibiotics are rendered ineffective. These compounds have a broad
therapeutic index providing a high degree of potency, good tolerability,
together with dosing versatility and flexibility.

Dr Soderquist received his Ph.D. from the University of Colorado in 1977 under
the direction of Professor Alfred Hassner. He later joined Professor H. C.
Brown at Purdue University as a post-doctoral associate where he worked on the
chemistry of organoboranes and organosilanes. He is the author of more than
130 research articles and four book chapters. He has made over 360 scientific
presentations around the world. Dr. Soderquist's reagents were selected by
Sigma-Aldrich Chemical Company to bear his name. Having Soderquist Reagents
available through their catalog is a significant accolade for Dr. Soderquist.
Recently, his work was highlighted in the American Chemical Society
publication "Noteworthy Chemistry." In addition, the prestigious journal
Angewandte Chemie selected one of his articles for its special chemical
highlights section. In 2000, Dr. Soderquist was the recipient of the "Boron
USA Award for Distinguished Accomplishment in Boron Science." He has won a
total of nine distinguished research awards at the University of Puerto Rico
and University of San Francisco.

Dr. Soderquist has graduated over twenty-four Ph.D. students and over eight
MS level students. He is also an advisor to BASF Corporation and Mine Safety
Appliances.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a mid-stage biopharmaceutical company focused on
developing its proprietary and patented Aganocide compounds, first-in-class,
stable, novel, synthetic anti-infective product candidates that are equivalent
to the active antimicrobial molecules generated within white blood cells to
treat and prevent a wide variety of infections without causing resistance.
NovaBay has internal development programs aimed at addressing hospital and
respiratory infections. The company has a licensing and research
collaboration agreement with Alcon, Inc. (NYSE: ACL) for use of its Aganocides
in the eye, ear and sinus, and in contact lens solutions. NovaBay has entered
into an agreement with Galderma S.A. to develop and commercialize Aganocides
in acne, impetigo and other dermatological indications. NovaBay(R) and
Aganocide(R) are trademarks of NovaBay Pharmaceuticals, Inc. For more
information on NovaBay, visit www.novabaypharma.com.

Cautionary Information Regarding Forward-Looking Statements

The statements in this press release regarding the potential efficacy of
NovaBay's Aganocide compounds are forward-looking statements. These statements
are subject to risks and uncertainties that could cause actual results to
differ materially from those projected in these forward-looking statements.
These risks and uncertainties include, among others, the risk that results
obtained in animal models may not be obtained in humans, and the risk of
unexpected delays in the regulatory process may delay the commencement or
completion of clinical trials. Other risks relating to NovaBay and its
Aganocide compounds, including risks that could cause actual results to differ
materially from those projected in the forward-looking statements in this
press release, are detailed in NovaBay's Annual Report on Form 10-K, under the
caption "Risk Factors" in Item 1A of Part I of that report, which was filed
with the Securities and Exchange Commission on March 31, 2009.

Contact:
NovaBay Pharmaceuticals, Inc.
Tom Paulson, 510-899-8809
Chief Financial Officer
tpaulson@novabaypharma.com

www.novabaypharma.com

Invigorate Communications
Investor Relations:
Gregory Gin, 908-376-7737
ggin@invigoratepr.com

Media Relations:
Mariesa Kemble, 608-850-4745
mkemble@invigoratepr.com

SOURCE NovaBay Pharmaceuticals, Inc.

Tom Paulson, Chief Financial Officer of NovaBay Pharmaceuticals, Inc.,
+1-510-899-8809, tpaulson@novabaypharma.com; or Investor Relations: Gregory
Gin, +1-908-376-7737, ggin@invigoratepr.com, or Media Relations: Mariesa
Kemble, +1-608-850-4745, mkemble@invigoratepr.com, both of Invigorate
Communications, for NovaBay Pharmaceuticals, Inc.